Skip to main content

Advertisement

Table 1 Participant characteristics by cohort (sequencing and replication) and group (control subjects and RRMS patients)

From: Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis

  Sequencing Cohort Replication Cohort
   Control Subjects (n = 9) RRMS Patients (n = 9) Control Subjects (n = 18) RRMS Patients (n = 20)
Female   100% 100% 100% 100%
Caucasian 100% 90% 94% 100%
Age (years) 34.75 (±11.45) 42.44 (±9.66) 38.92 (± 9.89) 38.39 (±9.41)
Disease Duration (years) N/A 15.11 (±11.87) N/A 9.29 (±.5.52)
EDSS Score 2.00 (±1.32) 2.09 (±1.53)
Age at Onset (years) 27.94 (±8.48) 28.96 (± 8.79)
Number of Relapses 5.98 (±4.91) 6.35 (± 3.33)
Days since Last Relapse 1083.00 (±1271.81) 985 (±969.75)
Treatment Off Treatment 2 0
Dimethyl fumarate 2 0
Fingolimod 3 10
Natalizumab 2 10
Time on Treatment (years) 2.46 (±2.60) 3.57 (±2.20)
Number of Relapses on Treatment 0.56 (±0.73) 1.50 (±2.12)
Most recent ARCSa 78.33 (±26.76) 81.35 (±20.43)
  1. Except for percentages and absolute numbers, all data is presented as mean (± SD). RRMS relapsing-remitting multiple sclerosis, EDSS extended disability status scale, ARCS audio-recorded cognitive screen, SD standard deviation of the mean. aARCS are only reported for patients who completed an ARCS within a year of sample collection (sequencing cohort n = 3; replication cohort n = 17)